Mariner
BEAM icon

Mariner’s Beam Therapeutics BEAM Stock Holding History

Mariner’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,448
Closed -$263K – 3493
2025
Q1 		$263K Sell
13,448
-440
-3% -$11.5K ﹤0.01% 2757
2024
Q4 		$344K Buy
13,888
+1,233
+10% +$31.5K ﹤0.01% 2506
2024
Q3 		$311K Buy
12,655
+3,266
+35% +$84.4K ﹤0.01% 2537
2024
Q2 		$220K Buy
9,389
+1,234
+15% +$30.3K ﹤0.01% 2715
2024
Q1 		$269K Buy
8,155
+529
+7% +$16.5K ﹤0.01% 2530
2023
Q4 		$208K Buy
+7,626
New +$189K ﹤0.01% 2666

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Mariner's BEAM Position: Q2 2025 in Review

Mariner sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 13,448 shares — an estimated $263K sold.

Mariner first reported a position in BEAM in Q4 2023 and held it in 6 quarters. The position peaked at $344K in Q4 2024. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • Mariner reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mariner sold 13,448 Beam Therapeutics shares in Q2 2025, an estimated $263K.
  • Mariner first reported a position in Beam Therapeutics in Q4 2023 and held it in 6 quarters.
  • Mariner's Beam Therapeutics position peaked at $344K in Q4 2024.
  • 217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.